MIODx said it has signed an exclusive license for two key immunotherapy technologies from the University of California, San Francisco.
The first technology provides a method to monitor a patient for response to immune checkpoint inhibitor therapy such as PD-L1 and CTLA-4. The second license extends the technology with a method to detect if a patient is likely to have an immune-related adverse event from their immunotherapy regimen.
MIODx also announced that they have entered into an agreement with UCSF to provide immunosequencing services as part of the validation and commercialization of the technology.
MIODx is a privately held company focused on discovery of early detection and prognostic cancer biomarkers through the company’s proprietary platforms. The company’s VerifyDx™ platform utilizes a highly sensitive, multiplex PCR assay and advanced bioinformatics to interrogate multiple DNA and RNA pathways that are implicated in highly metastatic cancer.
In addition to the VerifyDx platform, MIODx utilizes high throughput immune sequencing to generate information on T and B cell diversity that is being applied to monitoring a patient’s response to immunotherapy.
